Here are some articles that actually mentioned prostate cancer and GLP-1. Mostly in relation to Having fewer people get prostate cancer and fewer metastasis.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11479428/
ASCO highlighted four studies — some of which were published in its affiliated Journal of Clinical Oncology. The most prominent among them tracked medical and prescription records of over 10,000 patients with early-stage cancer, and found GLP-1s reduced cancer risk in 6 out of 7 cancers — four of them at statistically significant levels. Breast, liver, colorectal and non-small cell lung cancer risks declined significantly; kidney and prostate declined somewhat; pancreatic cancer rates were affected the least.
https://www.asco.org/about-asco/press-center/glp-may-reduce-metastatic-progression